Clinical Trial: Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07440537) titled 'Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study' on Feb. 10.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Cutaneous Lupus Erythematosus (CLE)

Intervention: DRUG: ICP-488 Tablets

Patients will receive ICP-488 orally as per the protocol

DRUG: ICP-488 Tablets

Patients will receive ICP-488 orally as per the protocol

OTHER: ICP-488 Pl...